Stock Track | Collegium Pharmaceutical Plummets 8.74% Intraday on Q4 Earnings and Revenue Misses

Stock Track02-26

Collegium Pharmaceutical's stock plummeted 8.74% during intraday trading on Thursday, following the release of its fourth-quarter financial results.

The biopharmaceutical company reported adjusted earnings per share of $2.04 for the quarter, which missed the analyst consensus estimate of $2.33 by 12.37%. Quarterly revenue came in at $205.4 million, a 13% year-over-year increase but slightly below the estimate of $206.4 million.

Despite the company reaffirming its full-year 2026 guidance and reporting strong growth in its Jornay PM product, the double miss on both earnings and revenue targets appears to have driven investor disappointment and the sharp sell-off.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198809733?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 23:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198809733","market":"hk","top_or_hot":-1,"title":"Stock Track | Collegium Pharmaceutical Plummets 8.74% Intraday on Q4 Earnings and Revenue Misses","media":"Stock Track","content":"<p>Collegium Pharmaceutical's stock plummeted 8.74% during intraday trading on Thursday, following the release of its fourth-quarter financial results.</p><p>The biopharmaceutical company reported adjusted earnings per share of $2.04 for the quarter, which missed the analyst consensus estimate of $2.33 by 12.37%. Quarterly revenue came in at $205.4 million, a 13% year-over-year increase but slightly below the estimate of $206.4 million.</p><p>Despite the company reaffirming its full-year 2026 guidance and reporting strong growth in its Jornay PM product, the double miss on both earnings and revenue targets appears to have driven investor disappointment and the sharp sell-off.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Collegium Pharmaceutical Plummets 8.74% Intraday on Q4 Earnings and Revenue Misses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Collegium Pharmaceutical Plummets 8.74% Intraday on Q4 Earnings and Revenue Misses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 23:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Collegium Pharmaceutical's stock plummeted 8.74% during intraday trading on Thursday, following the release of its fourth-quarter financial results.</p><p>The biopharmaceutical company reported adjusted earnings per share of $2.04 for the quarter, which missed the analyst consensus estimate of $2.33 by 12.37%. Quarterly revenue came in at $205.4 million, a 13% year-over-year increase but slightly below the estimate of $206.4 million.</p><p>Despite the company reaffirming its full-year 2026 guidance and reporting strong growth in its Jornay PM product, the double miss on both earnings and revenue targets appears to have driven investor disappointment and the sharp sell-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COLL","symbol_name":"Collegium Pharmaceutical, Inc.","start_time":0,"source_url":"","article_id":"1198809733","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198809733","pubTimestamp":1772118785,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Collegium Pharmaceutical's stock plummeted 8.74% during intraday trading on Thursday, following the release of its fourth-quarter financial results.The biopharmaceutical company reported adjusted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COLL":"Collegium Pharmaceutical, Inc."},"translate_title":"个股追踪|Collegium Pharmaceutical盘中暴跌8.74%因Q4盈利营收不及","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COLL":1},"content_text":"Collegium Pharmaceutical's stock plummeted 8.74% during intraday trading on Thursday, following the release of its fourth-quarter financial results.The biopharmaceutical company reported adjusted earnings per share of $2.04 for the quarter, which missed the analyst consensus estimate of $2.33 by 12.37%. Quarterly revenue came in at $205.4 million, a 13% year-over-year increase but slightly below the estimate of $206.4 million.Despite the company reaffirming its full-year 2026 guidance and reporting strong growth in its Jornay PM product, the double miss on both earnings and revenue targets appears to have driven investor disappointment and the sharp sell-off.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198809733","isCrawlerRequest":true}